GlassScriptPhysician profile
Destin Knowles Vantyle
NPI 1134779440
$3,963.15
in general payments reported to CMS, 2019-2025
18 companies · $357 in 2025
The $357 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,461 · 2022: $1,713 · 2023: $366 · 2024: $65.98 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $789.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $742.95 | 2021-2025 | Uzedy |
| Abbvie INC. | $714.17 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $583.46 | 2021-2023 | Spravato, Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $315.78 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Otsuka America Pharmaceutical, INC. | $287.99 | 2021-2025 | Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $230.42 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $214.70 | 2021-2025 | Trintellix |
| Alkermes, INC. | $186.61 | 2021-2025 | Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $175.49 | 2021-2024 | Caplyta |
| Neurocrine Biosciences, INC. | $138.03 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $123.39 | 2022-2025 | Fanapt |
| Bausch Health US, LLC | $94.70 | 2021-2025 | Aplenzin |
| Tris Pharma INC | $48.27 | 2025 | Dyanavel Xr |
| Corium, LLC | $40.27 | 2022 | |
| Redhill Biopharma INC. | $21.81 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $18.79 | 2025 | Auvelity |
| Noven Therapeutics, LLC | $14.84 | 2023 | Secuado |
| Supernus Pharmaceuticals, INC. | $11.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Destin Vantyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.